Compounding is another grey area distribution method
You May Need to Use a GLP-1 Indefinitely While we dont yet have good data on what happens when people with MASH stop taking the medication, its reasonable to assume that their excess liver fat and scar tissue may come back, even if your MASH is in remission, says Ali
As obesity is known to increase the risk of cardiovascular disease, including HF, therefore, anti-obesity interventions like tirzepatide may have cardioprotective effects [101]
The beneficial effects of GLP-1 RAs on HRQoL and other outcomes in HFpEF are likely due to pleiotropic impacts, related or not to weight reduction, such as decongestion (mainly due to the reduction of increased plasma volume associated with obesity and epicardial constrain), reverse cardiac remodelling (mainly due to the decrease in epicardial fat and regression of left atrial and LV myopathy, lowering intracardiac pressure) and anti-inflammatory actions, among others
While GLP-1 receptor agonist therapy leads to greater relative fat loss than lean mass loss, preserving muscle tissue requires adequate protein intake and resistance exercise during weight reduction
